Analyst consensus rating
Royalty Pharma Analyst Rating: Buy
Direct answer
Royalty Pharma's consensus rating is Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $75.25.
Forecast evidence checked November 21, 2026.
Get free Royalty Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $68.45
- Average price target
- $75.25
- High price target
- $80.00
- Low price target
- $67.00
- Low target gap
- -2.1%
- Target upside
- +9.9%
- High target gap
- +16.9%
- Target range width
- 19%
- Consensus rating
- Buy
- Analysts
- 8
- Evidence date
- November 21, 2026
- Valid through
- November 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Royalty Pharma?
Royalty Pharma has a verified Buy consensus. The same dataset has an average price target of $75.25.
How far are Royalty Pharma's low and high targets from the recorded price?
The low target implies -2.1%, while the high target implies +16.9%.
How many analysts are included in Royalty Pharma's consensus?
The verified consensus includes 8 analysts.
How is Royalty Pharma's target upside or downside calculated?
The average target of $75.25 is divided by the recorded price of $68.45, then one is subtracted to produce +9.9%. This does not guarantee a future return.
When was Royalty Pharma's analyst forecast verified?
The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.